Efficacy News and Research

RSS

Study explains why south Asians have high susceptibility to developing type 2 diabetes

Lower amounts of brown adipose tissue (BAT, or ‘brown fat’) could help explain why south Asians—who make up a fifth of the world’s population—have an exceptionally high susceptibility to developing metabolic problems such as obesity and type 2 diabetes.

13 Nov 2013

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today the completion of patient enrolment for its first clinical trial.

12 Nov 2013

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.

12 Nov 2013

FDA Advisory Committee votes in favor of Cochlear Nucleus Hybrid L24 Implant System

Cochlear Limited, the global leader in implantable hearing solutions, announced today that an advisory committee to the US Food and Drug Administration voted favorably on the Cochlear Nucleus Hybrid L24 Implant System.

12 Nov 2013

Nontoxic therapy shows encouraging results in blood samples from lupus patients

Northwestern Medicine- scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease.

12 Nov 2013

Father's cocaine use may make sons less sensitive to drug and more likely to resist addictive behaviors

A father's cocaine use may make his sons less sensitive to the drug and thereby more likely to resist addictive behaviors, suggests new findings from an animal study presented by Penn Medicine researchers at Neuroscience 2013, the annual meeting of the Society for Neuroscience.

12 Nov 2013

ICS overuse warning in COPD

Researchers from the UK caution that inhaled corticosteroids are being overused in patients with chronic obstructive pulmonary disease, in light of a lack of solid evidence for their efficacy, limited guideline support, and growing concerns over their association with pneumonia.

11 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

As of September 30, 2013, Delmar Pharmaceuticals has cash and equivalents of approximately $5.2 million and its working capital balance is in line with its expectations.

11 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

ReShape Duo Intragastric Balloon treatment for weight loss meets primary efficacy endpoints

ReShape Medical, Inc. today announced that its REDUCE Trial for the ReShape Duo Intragastric Balloon, a non-surgical treatment for weight loss, has met its primary efficacy endpoints.

11 Nov 2013

New therapeutic at-home gaming program for stroke patients

Researchers at The Ohio State University Wexner Medical Center have developed a therapeutic at-home gaming program for stroke patients who experience motor weakness affecting 80 percent of survivors.

11 Nov 2013

Drug used to treat intestinal worms could protect people from periodontitis, says study

A drug currently used to treat intestinal worms could protect people from periodontitis, an advanced gum disease, which untreated can erode the structures-including bone-that hold the teeth in the jaw. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.

11 Nov 2013

GLP-1 hormone can predict metabolic efficacy of gastric bypass

The sensitivity of the GLP-1 hormone, which is secreted by the gastrointestinal tract, can predict the metabolic efficacy of a gastric bypass. The use of a GLP1 challenge could thus function as a novel predictive biomarker for personalized treatment of type 2 diabetes and obesity.

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

$Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D$

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs.

8 Nov 2013

Nanoparticles with chemotherapeutic drugs can kill drug-resistant breast cancer cells

Nanoparticles filled with chemotherapeutic drugs can kill drug-resistant breast cancer cells, according to a study published in the scientific journal Biomaterials.

8 Nov 2013

Efficacy News and Research

Study explains why south Asians have high susceptibility to developing type 2 diabetes

Promethera Biosciences completes patient enrolment for first clinical trial of HepaStem

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

FDA Advisory Committee votes in favor of Cochlear Nucleus Hybrid L24 Implant System

Nontoxic therapy shows encouraging results in blood samples from lupus patients

Father's cocaine use may make sons less sensitive to drug and more likely to resist addictive behaviors

ICS overuse warning in COPD

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Delmar Pharmaceuticals announces quarterly update, strengthens intellectual property portfolio

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

ReShape Duo Intragastric Balloon treatment for weight loss meets primary efficacy endpoints

New therapeutic at-home gaming program for stroke patients

Drug used to treat intestinal worms could protect people from periodontitis, says study

GLP-1 hormone can predict metabolic efficacy of gastric bypass

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

Nanoparticles with chemotherapeutic drugs can kill drug-resistant breast cancer cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News